// App-Quantinova.ai

TCT-30 : Safety, Clinical Performance and multi-modality imaging data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 12-month follow-up-BIOSOLVE-II

Researchers

Presenter

  • Huseyin Ince

Principal Investigators

  • Alexandre Abizaid

  • Ralph Toelg

  • Pedro Lemos

  • Clemens von Birgelen

  • Evald Christiansen

  • William Wijns

  • Franz-Josef Neumann

  • Christoph Kaiser

  • Eric Eeckhout

Medical Centers

  • Herzzentrum Segeberger Kliniken, Henstedt-Ulzburg, Germany

  • Aarhus University Hospital, Aarhus, Denmark

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

  • University Hospital Basel, Basel, Switzerland

  • Unknown, Aalst, Belgium

  • Thoraxcentrum Twente, Enschede, Netherlands

  • Lukaskrankenhaus GmbH Neuss, Neuss, Germany

  • CHUV, Lausanne, Switzerland

  • MedStar Heart institute, Washington, District of Columbia, United States

  • Cardiology, University Hospital CHUV,

  • Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany

  • University of Sao Paulo Medical School, Sao Paulo, Brazil

Locations

  • Brazil

  • Singapore

  • Netherlands

  • Germany

  • Spain

  • Switzerland

  • United States

  • Denmark

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Nitroglycerin

  • Acetylcholine

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved